Collaboration to Advance Data Visualization and Discovery Platform
|
By LabMedica International staff writers Posted on 02 Oct 2012 |
PerkinElmer, Inc. (Waltham, MA, USA) and Tibco Software, Inc. (Palo Alto, CA, USA), the provider of Tibco Spotfire, a leading analytics and data discovery platform, announced that they have entered into an exclusive strategic relationship.
Under the terms of this new agreement, PerkinElmer has licensed the exclusive, worldwide rights to the Tibco Spotfire software platform in specific scientific research and development markets. These markets include basic and preclinical development applications in life sciences as well as R&D, quality assurance and quality control applications in chemical, petrochemical, environmental, food and beverage, consumer products, and academia.
This alliance will combine the depth and strength of PerkinElmer’s domain knowledge and systems with the analytic capabilities of Tibco Spotfire to provide a broader, richer set of analytic solutions for the research market. As a result, PerkinElmer will take responsibility for growing and servicing the Tibco Spotfire business in these markets.
“How scientists capture and visualize their data through the Tibco Spotfire platform is fundamental to how scientists conduct their work. Spotfire is a critical data analysis tool for the R&D community and complements PerkinElmer’s informatics offering by adding search and data visualization, which are among the most pressing business requirements of life sciences, diagnostics and environmental laboratories, worldwide,” said Mike Stapleton, general manager of informatics at PerkinElmer. “Through this strategic relationship, we are very excited to offer scientists a complete package of data generation, data management as well as data analysis and visualization to better harness information for more informed insights and decisions. The interoperability of PerkinElmer’s E-Notebook with the Tibco Spotfire platform puts all information in one place for our customers.”
One of the biggest hurdles for scientists now is the volume and diversity of data they need to gather and study to make knowledgeable and informed decisions that impact both research and business intelligence efforts. The Tibco Spotfire platform helps complete the analysis workflow by adding real time data interpretation to existing data generation and assembly tools. The data visualization tool enables researchers to instantly visualize and share data across an enterprise to reveal opportunities, avoid risks, and anticipate trends. This system can be applied to nearly every type of science and can analyze data from virtually any instrument platform.
“This new relationship is exciting news for research scientists. Our relationship with PerkinElmer will enable a broader community to benefit from the Tibco Spotfire platform and will expand the range and depth of applications serving the rapidly evolving needs of scientific research,” said Christian Marcazzo, co-head of global life sciences for Spotfire at Tibco Software Inc.
PerkinElmer is a provider of discovery, collaboration, and knowledge enterprise solutions, desktop software, scientific databases, and consulting services to the pharmaceutical, biotechnology, and chemical industries. The Company offers enterprise solutions, desktop software, scientific databases, and professional services for biotechnology, drug discovery and chemical research, including software, databases, and web sites that enable customers to create, analyze, and communicate chemical, biologic, and scientific data more effectively. The company reported revenue of approximately USD 1.9 billion in 2011, has approximately 7,000 employees serving customers in more than 150 countries.
Tibco Software is a provider of infrastructure software for companies to use on-premise or as part of cloud computing environments. Tibco Spotfire is the company’s in-memory analytics software for next-generation business intelligence. By offering a visual, interactive experience, Spotfire helps professionals rapidly discover new and actionable insights in information.
Related Links:
PerkinElmer
Tibco
Under the terms of this new agreement, PerkinElmer has licensed the exclusive, worldwide rights to the Tibco Spotfire software platform in specific scientific research and development markets. These markets include basic and preclinical development applications in life sciences as well as R&D, quality assurance and quality control applications in chemical, petrochemical, environmental, food and beverage, consumer products, and academia.
This alliance will combine the depth and strength of PerkinElmer’s domain knowledge and systems with the analytic capabilities of Tibco Spotfire to provide a broader, richer set of analytic solutions for the research market. As a result, PerkinElmer will take responsibility for growing and servicing the Tibco Spotfire business in these markets.
“How scientists capture and visualize their data through the Tibco Spotfire platform is fundamental to how scientists conduct their work. Spotfire is a critical data analysis tool for the R&D community and complements PerkinElmer’s informatics offering by adding search and data visualization, which are among the most pressing business requirements of life sciences, diagnostics and environmental laboratories, worldwide,” said Mike Stapleton, general manager of informatics at PerkinElmer. “Through this strategic relationship, we are very excited to offer scientists a complete package of data generation, data management as well as data analysis and visualization to better harness information for more informed insights and decisions. The interoperability of PerkinElmer’s E-Notebook with the Tibco Spotfire platform puts all information in one place for our customers.”
One of the biggest hurdles for scientists now is the volume and diversity of data they need to gather and study to make knowledgeable and informed decisions that impact both research and business intelligence efforts. The Tibco Spotfire platform helps complete the analysis workflow by adding real time data interpretation to existing data generation and assembly tools. The data visualization tool enables researchers to instantly visualize and share data across an enterprise to reveal opportunities, avoid risks, and anticipate trends. This system can be applied to nearly every type of science and can analyze data from virtually any instrument platform.
“This new relationship is exciting news for research scientists. Our relationship with PerkinElmer will enable a broader community to benefit from the Tibco Spotfire platform and will expand the range and depth of applications serving the rapidly evolving needs of scientific research,” said Christian Marcazzo, co-head of global life sciences for Spotfire at Tibco Software Inc.
PerkinElmer is a provider of discovery, collaboration, and knowledge enterprise solutions, desktop software, scientific databases, and consulting services to the pharmaceutical, biotechnology, and chemical industries. The Company offers enterprise solutions, desktop software, scientific databases, and professional services for biotechnology, drug discovery and chemical research, including software, databases, and web sites that enable customers to create, analyze, and communicate chemical, biologic, and scientific data more effectively. The company reported revenue of approximately USD 1.9 billion in 2011, has approximately 7,000 employees serving customers in more than 150 countries.
Tibco Software is a provider of infrastructure software for companies to use on-premise or as part of cloud computing environments. Tibco Spotfire is the company’s in-memory analytics software for next-generation business intelligence. By offering a visual, interactive experience, Spotfire helps professionals rapidly discover new and actionable insights in information.
Related Links:
PerkinElmer
Tibco
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







